Charles Ritchie

Charles Ritchie

Auto-generated profile, based on publicly available information

Charles Ritchie

Mayo Clinic Florida

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Verified
Journal Article
Open access
KZKarim A. Zaazoue
Karim A. Zaazoue
MMMathew R. McCann
Mathew R. McCann
AAAhmed K. Ahmed
Ahmed K. Ahmed
ICIsabel O. Cortopassi
Isabel O. Cortopassi
YEYoung M. Erben
Young M. Erben
CRCharles A. Ritchie
Charles A. Ritchie
To investigate the performance of a commercially available artificial intelligence (AI) algorithm for the detection of pulmonary embolism (PE) on contrast-enhanced computed tomography (CT) scans in patients hospitalized for coronavirus disease 2019 (COVID-19). Retrospective analysis was performed of all contrast-enhanced chest CT scans of patients admitted for COVID-19 between March 1, 2020 and December 31, 2021. Based on the original radiology reports, all PE-positive examinations were included (n=527). Using a reversed-flow single-gate diagnostic accuracy case-control model, a randomly selected cohort of PE-negative examinations (n=977) was included. Pulmonary parenchymal disease severity was assessed for all the included studies using a semiquantitative system, the total severity score. All included CT scans were sent for interpretation by the commercially available AI algorithm, Aidoc. Discrepancies between AI and original radiology reports were resolved by 3 blinded radiologists, who rendered a final determination of indeterminate, positive, or negative. A total of 78 studies were found to be discrepant, of which 13 (16.6%) were deemed indeterminate by readers and were excluded. The sensitivity and specificity of AI were 93.2% (95% CI, 90.6%-95.2%) and 99.6% (95% CI, 98.9%-99.9%), respectively. The accuracy of AI for all total severity score groups (mild, moderate, and severe) was high (98.4%, 96.7%, and 97.2%, respectively). Artificial intelligence was more accurate in PE detection on CT pulmonary angiography scans than on contrast-enhanced CT scans (P<.001), with an optimal Hounsfield unit of 362 (P=.048). The AI algorithm demonstrated high sensitivity, specificity, and accuracy for PE on contrast-enhanced CT scans in patients with COVID-19 regardless of parenchymal disease. Accuracy was significantly affected by the mean attenuation of the pulmonary vasculature. How this affects the legitimacy of the binary outcomes reported by AI is not yet known.

2 December 2019 in Seminars in Interventional Radiology
Verified
Journal Article
Closed access
PDF file
VPVipulkumar Patel
Vipulkumar Patel
CRCharles A. Ritchie
Charles A. Ritchie
CPCarlos Padula
Carlos Padula
JMJ. Mark McKinney
J. Mark McKinney
Radiofrequency ablation (RFA) is one of the first developed minimally invasive definitive cancer therapies. The safety and efficacy of RFA is well documented and has led to its incorporation into multiple international societal guidelines. By expanding on the body of knowledge acquired during the clinical use of RFA, alternative ablative technologies have emerged and are successfully competing for locoregional therapy market share. The adaption of newer ablative technologies is leading to a rapid decline in the utilization of RFA by interventional radiologists despite the lack of proven superiority. In their 2010 article, Hong and Georgiades stated “… RFA is likely to remain the mainstay of ablations for small tumors until sufficient experience emerges for the widespread acceptance for alternative ablative modalities.” Within a decade of this publication, has this time arrived?

1 September 2021 in Journal of Vascular Surgery Cases, Innovations and Techniques
Verified
Journal Article
Open access
MEMohamed Elboraey
Mohamed Elboraey
BTBeau B Toskich
Beau B Toskich
ALAndrew R. Lewis
Andrew R. Lewis
CRCharles A. Ritchie
Charles A. Ritchie
GFGregory T. Frey
Gregory T. Frey
ZDZlatko Devcic
Zlatko Devcic
The use of a Viabahn VBX endoprosthesis (W. L. Gore & Associates, Flagstaff, Ariz) to exclude chronically thrombosed inferior vena cava (IVC) filters refractory to exclusion with self-expanding stents was evaluated. The mean duration of TrapEase IVC (Cordis, Milpitas, Calif) implantation was 7.6 years (range, 2-11 years). Symptoms included leg pain, edema, color changes, and back pain. The mean Villalta score and venous clinical severity score were 17 (range, 13-23) and 13 (range, 11-15), respectively. Indirect ultrasound evidence of stent patency was demonstrated at a mean of 8 months after intervention. The mean Villalta score and venous clinical severity score had decreased by 13 and 10, respectively, at a mean of 9.5 months after intervention. Iliocaval reconstruction with Viabahn VBX balloon expandable stent-graft exclusion of chronically thrombosed TrapEase IVC filters is safe, with favorable short-term results.

1 June 2019 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
CRCharles Ritchie
Charles Ritchie
RPRicardo Paz-Fumagalli
Ricardo Paz-Fumagalli
GFGregory Frey
Gregory Frey
BTBeau Toskich
Beau Toskich

1 September 2021 in Journal of Vascular Surgery Cases, Innovations and Techniques
Verified
Journal Article
Open access
VRVamsi Reddy
Vamsi Reddy
NTNathan Todnem
Nathan Todnem
CFCamila Franco-Mesa
Camila Franco-Mesa
YEYoung M. Erben
Young M. Erben
RTRabih G. Tawk
Rabih G. Tawk
CRCharles Ritchie
Charles Ritchie
We present a case of a common femoral artery repair after losing access to the vessel in a 67-year-old woman using a Mynx-Grip vascular closure device. The hematoma over the right common femoral artery was accessed under fluoroscopic guidance. Then, the balloon of the closure device was inflated inside the artery and pulled back against the origin of the puncture site into the common femoral artery. Finally, the collagen plug was deployed and pressed against the outside of the vessel to occlude the puncture site.

9 July 2022 in Annals of Vascular Surgery - Brief Reports and Innovations
Verified
Journal Article
Open access
RGRoberta Lozano Gonzalez
Roberta Lozano Gonzalez
CRCharles Ritchie
Charles Ritchie
AFAna Fuentes-Perez
Ana Fuentes-Perez
YEYoung Erben
Young Erben